<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070692</url>
  </required_header>
  <id_info>
    <org_study_id>SFPRF14-1</org_study_id>
    <secondary_id>SFPRF14-1</secondary_id>
    <nct_id>NCT02070692</nct_id>
  </id_info>
  <brief_title>Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users</brief_title>
  <official_title>Tamoxifen for the Treatment of Unfavorable Bleeding Patterns in Etonogestrel Contraceptive Implant Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal
      bleeding in women who are using the Etonogestrel contraceptive implant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nearly all of the 3 million unintended pregnancies in the United States each year result from
      inconsistent or non-use of contraception. Increasing use of the most effective methods of
      contraception will reduce unintended pregnancies and their social, medical and economic
      consequences. The contraceptive etonogestrel implant (ENG implant) is 20 times more effective
      at pregnancy prevention than oral contraceptive pills, but it has bleeding side effects that
      make it unappealing for many women. Tamoxifen, a selective estrogen receptor modulator (SERM)
      used most commonly for adjuvant treatment of breast cancer, has previously been shown to
      dramatically reduce bleeding in users of an older levonorgestrel-based contraceptive implant
      (Norplant tm). It has not been studied in newer progestin-based methods such as the ENG
      implant. If tamoxifen could stop bleeding in users of the ENG implant, it would give patients
      and physicians a valuable option for management of progestin-induced irregular bleeding. This
      research project will test the effectiveness of tamoxifen taken on an as-needed basis to
      treat abnormal bleeding in ENG implant users. If tamoxifen can be established as an effective
      treatment for frequent or prolonged bleeding, it will increase the acceptability of the ENG
      implant, increase its use and reduce unintended pregnancies. This is the first project to
      evaluate tamoxifen for treatment of unfavorable bleeding in users of the ENG contraceptive
      implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Days</measure>
    <time_frame>180 days</time_frame>
    <description>The primary objective of this study is to determine whether tamoxifen taken by users of the ENG implant on an as-needed basis for frequent or prolonged bleeding can reduce the number of bleeding days by at least 40% over 180 days, when compared to placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding/Spotting Days</measure>
    <time_frame>30 days</time_frame>
    <description>Bleeding/spotting days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Consecutive Bleeding-free Days After Study Drug</measure>
    <time_frame>up to 180 days</time_frame>
    <description>Consecutive bleeding-free days after study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction (as Recorded on a 100mm Visual Analog Scale Where 0 is Not at All Satisfied and 100mm is Completely Satisfied)</measure>
    <time_frame>180 days</time_frame>
    <description>Secondary objective is to determine whether tamoxifen can improve satisfaction with the implant and with bleeding patterns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Ovulation After First Use of Study Drug</measure>
    <time_frame>30 days</time_frame>
    <description>A third secondary objective is to determine whether taking tamoxifen at this dose compromises ovulation suppression in ENG users. Tamoxifen is known to transiently raise serum estradiol levels, but does not affect gonadotropin release in premenopausal women. Therefore, it is unlikely to interact with the ovulation suppression provided by the implant. However, to further investigate any theoretical interaction between tamoxifen and etonogestrel, urine markers of ovulation will be collected to document ongoing ovulation suppression with intermittent tamoxifen use.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Menstruation Disturbances</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>7 day course of placebo during an episode of irregular vaginal bleeding</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current user of the etonogestrel implant (Nexplanon, Implanon) for at least one month

          -  Experiencing bleeding episodes more frequently than every 24 days, or a single episode
             of bleeding lasting longer than 14 days

          -  English or Spanish speaking

          -  Planning to continue implant use for six months

          -  Access to a cell phone that can accept and send text messages

        Exclusion Criteria:

          -  Postpartum within six months

          -  Post-abortion within six weeks

          -  Pregnant

          -  Breast-feeding

          -  Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant

          -  Bleeding dyscrasia

          -  Anticoagulation use

          -  Active cervicitis

          -  Allergy to tamoxifen

          -  History of venous thromboembolism

          -  Current or past breast or uterine malignancy

          -  Use of medication contraindicated with tamoxifen (coumadin, letrozole, bromocriptine,
             rifampicin, aminoglutethimide, phenobarbital)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsu.edu/xd/health/services/women/clinical-trials/open-studies/index.cfm</url>
    <description>OHSU Women's Health clinical trials</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Katharine Simmons, MD</investigator_full_name>
    <investigator_title>Fellow in Family Planning</investigator_title>
  </responsible_party>
  <keyword>Contraceptive implant</keyword>
  <keyword>Irregular vaginal bleeding</keyword>
  <keyword>Etonogestrel implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study under review for publication</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tamoxifen</title>
          <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tamoxifen</title>
          <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" lower_limit="18" upper_limit="36"/>
                    <measurement group_id="B2" value="23.9" lower_limit="15" upper_limit="38"/>
                    <measurement group_id="B3" value="24.6" lower_limit="15" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days of bleeding/spotting in 30 days prior to enrollment</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.3" spread="8.5"/>
                    <measurement group_id="B2" value="22.2" spread="6.6"/>
                    <measurement group_id="B3" value="19.75" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Days</title>
        <description>The primary objective of this study is to determine whether tamoxifen taken by users of the ENG implant on an as-needed basis for frequent or prolonged bleeding can reduce the number of bleeding days by at least 40% over 180 days, when compared to placebo.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Days</title>
          <description>The primary objective of this study is to determine whether tamoxifen taken by users of the ENG implant on an as-needed basis for frequent or prolonged bleeding can reduce the number of bleeding days by at least 40% over 180 days, when compared to placebo.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" spread="37.5"/>
                    <measurement group_id="O2" value="46.9" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bleeding/Spotting Days</title>
        <description>Bleeding/spotting days</description>
        <time_frame>30 days</time_frame>
        <population>Number of patients analyzed is number of patients who completed 30 days of follow up. Two subjects in the tamoxifen arm and three in the placebo arm were lost to follow up prior to 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding/Spotting Days</title>
          <description>Bleeding/spotting days</description>
          <population>Number of patients analyzed is number of patients who completed 30 days of follow up. Two subjects in the tamoxifen arm and three in the placebo arm were lost to follow up prior to 30 days.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="9.0"/>
                    <measurement group_id="O2" value="15.5" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Consecutive Bleeding-free Days After Study Drug</title>
        <description>Consecutive bleeding-free days after study drug</description>
        <time_frame>up to 180 days</time_frame>
        <population>Number of subjects analyzed is the number of subjects who started taking the study drug. One subject in the tamoxifen arm and there in the placebo arm did not initiate study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
          </group>
        </group_list>
        <measure>
          <title>Consecutive Bleeding-free Days After Study Drug</title>
          <description>Consecutive bleeding-free days after study drug</description>
          <population>Number of subjects analyzed is the number of subjects who started taking the study drug. One subject in the tamoxifen arm and there in the placebo arm did not initiate study drug.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="24.5"/>
                    <measurement group_id="O2" value="13.6" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction (as Recorded on a 100mm Visual Analog Scale Where 0 is Not at All Satisfied and 100mm is Completely Satisfied)</title>
        <description>Secondary objective is to determine whether tamoxifen can improve satisfaction with the implant and with bleeding patterns.</description>
        <time_frame>180 days</time_frame>
        <population>Number of subjects analyzed is the number of subjects who completed a final study visit (either completion of full study or early termination visit) to provide a final estimation of satisfaction.</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction (as Recorded on a 100mm Visual Analog Scale Where 0 is Not at All Satisfied and 100mm is Completely Satisfied)</title>
          <description>Secondary objective is to determine whether tamoxifen can improve satisfaction with the implant and with bleeding patterns.</description>
          <population>Number of subjects analyzed is the number of subjects who completed a final study visit (either completion of full study or early termination visit) to provide a final estimation of satisfaction.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" spread="24.7"/>
                    <measurement group_id="O2" value="53.6" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Ovulation After First Use of Study Drug</title>
        <description>A third secondary objective is to determine whether taking tamoxifen at this dose compromises ovulation suppression in ENG users. Tamoxifen is known to transiently raise serum estradiol levels, but does not affect gonadotropin release in premenopausal women. Therefore, it is unlikely to interact with the ovulation suppression provided by the implant. However, to further investigate any theoretical interaction between tamoxifen and etonogestrel, urine markers of ovulation will be collected to document ongoing ovulation suppression with intermittent tamoxifen use.</description>
        <time_frame>30 days</time_frame>
        <population>Number of subjects analyzed are those that provided urine samples. No subject who provided urine samples was excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Ovulation After First Use of Study Drug</title>
          <description>A third secondary objective is to determine whether taking tamoxifen at this dose compromises ovulation suppression in ENG users. Tamoxifen is known to transiently raise serum estradiol levels, but does not affect gonadotropin release in premenopausal women. Therefore, it is unlikely to interact with the ovulation suppression provided by the implant. However, to further investigate any theoretical interaction between tamoxifen and etonogestrel, urine markers of ovulation will be collected to document ongoing ovulation suppression with intermittent tamoxifen use.</description>
          <population>Number of subjects analyzed are those that provided urine samples. No subject who provided urine samples was excluded from this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tamoxifen</title>
          <description>Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
Placebo: 7 day course of placebo during an episode of irregular vaginal bleeding</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Katharine Simmons</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>404-718-6619</phone>
      <email>simmonka@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

